高级搜索
多西他赛联合顺铂、5-Fu及亚叶酸钙治疗晚期胃癌[J]. 肿瘤防治研究, 2008, 35(08): 590-592. DOI: 10.3971/j.issn.1000-8578.3104
引用本文: 多西他赛联合顺铂、5-Fu及亚叶酸钙治疗晚期胃癌[J]. 肿瘤防治研究, 2008, 35(08): 590-592. DOI: 10.3971/j.issn.1000-8578.3104
Effects of Docetaxel,Cisplatin Fluorouracil and Calcium Folinate in Treatment of Patients with Advanced Stomach Cancer[J]. Cancer Research on Prevention and Treatment, 2008, 35(08): 590-592. DOI: 10.3971/j.issn.1000-8578.3104
Citation: Effects of Docetaxel,Cisplatin Fluorouracil and Calcium Folinate in Treatment of Patients with Advanced Stomach Cancer[J]. Cancer Research on Prevention and Treatment, 2008, 35(08): 590-592. DOI: 10.3971/j.issn.1000-8578.3104

多西他赛联合顺铂、5-Fu及亚叶酸钙治疗晚期胃癌

Effects of Docetaxel,Cisplatin Fluorouracil and Calcium Folinate in Treatment of Patients with Advanced Stomach Cancer

  • 摘要: 目的研究多西他赛联合顺铂、5-Fu及亚叶酸钙治疗晚期胃癌的临床疗效。方法试验组52例化疗方案:多西他赛75mg/m2d1,5-Fu500mg/m2d1~5,亚叶酸钙200mg/m2d1~5,顺铂20mg/m2d1~5,3周重复;对照组47例治疗用表阿霉素(EPI)35mg/m2,静脉推注,顺铂40mg/m2,亚叶酸钙250mg/m2,5-Fu425mg/m2,静脉滴注,1次/周,连用8周评定疗效。结果试验组有效率为59.6%,无进展中位生存期7.8月,1年、2年生存率分别是51%和19%。对照组有效率为46.8%,无进展中位生存期6.0月,1年、2年生存率分别是47%和9%。两组有效率和1年生存率比较差异无统计学意义(P>0.05);两组有效中位无进展生存期和2年生存率比较差异有统计学意义(P<0.05)。毒副作用主要为胃肠道反应和骨髓毒性,但大部分患者可以耐受。结论多西他赛联合顺铂、5-Fu及亚叶酸钙是治疗晚期胃癌安全有效的方案。

     

    Abstract: Objective To evaluate the efficacy and toxicity of the combination of docetaxel,5-fluorouracil(5-Fu) and calcium folinate(CF) in the treatment of patients with advanced stomach cancer. Methods Group A: The 52 patients with advanced stomach cancer received Docetaxel 75mg/m2 iv,and 5-Fu 500mg/m2 dl~5iv,CF200mg/m2dl~5iv.Cisplatin﹙DDP﹚20mg/m2 dl~5,A cycle is 3 weeks.Group B: 47 patients received EPI 35mg/m2,DDP,CF 250mg/m2and 5-Fu 425mg/m2.A cycle is 1 weeks and 8 cycles is a course of treatment. Results  The overall response rate of Group A was 59. 6 % and the overall response of the cont rol of Group B was 46. 8 %. The progression f ree median duration of responsive patient s was 7. 8 months in Group A and 6. 0 months in Group B. 1- and 2-year survival rate in Group A was 51 % and 19 %, and in Group B were 47 % and 9 %. There was no obvious difference between overall response rates and 1-year survival rate of two groups ( P > 0. 05) . The progression f ree median duration of responsive patient s and 2-year survival rate were significantly difference between two groups ( P <0. 05) . The major side effect s include phlebitis and peripheral neuritis can be accepted by most of the patient s. Conclusion  Combination of Docetaxel, CF and 5-Fu is an effective regimen in the t reatment of patient s with advanced stomach cancer.

     

/

返回文章
返回